LEXINGTON, Mass., Aug. 19, 2019 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM) has received a grant from the United
States Patent and Trademark Office for US Pat. No. 10376465.
Granted claims cover iSPERSE formulations of the company's lead
pipeline program Pulmazole. The patent, entitled "Monovalent
Metal Cation Dry Powders for Inhalation", protects formulations
that contain an anti-fungal agent with iSPERSE formulations.
iSPERSE is Pulmatrix's proprietary inhaled engineered particle
technology.
"The expansion of our iSPERSE intellectual property rights in
the United States builds upon our
growing worldwide patent estate supporting our platform technology
and our proprietary programs. This patent is a valuable step
in supporting the development of our lead anti-fungal program to
serve unmet needs of patients worldwide," said Ted Raad, chief executive officer of
Pulmatrix.
About Pulmatrix
Pulmatrix is a clinical stage
biopharmaceutical company developing innovative inhaled therapies
to address serious pulmonary disease using its patented iSPERSE™
technology. The Company's proprietary product pipeline is focused
on advancing treatments for serious lung diseases, including
Pulmazole, an inhaled anti-fungal for patients with allergic
bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow
spectrum kinase inhibitor for patients with obstructive lung
diseases including asthma and chronic obstructive pulmonary disease
("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its
proprietary engineered dry powder delivery platform, which seeks to
improve therapeutic delivery to the lungs by maximizing local
concentrations and reducing systemic side effects to improve
patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this
press release that are forward-looking and not statements of
historical fact are forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements of historical fact, and may be
identified by words such as "anticipates," "assumes," "believes,"
"can," "could," "estimates," "expects," "forecasts," "guides,"
"intends," "is confident that", "may," "plans," "seeks,"
"projects," "targets," and "would," and their opposites and similar
expressions are intended to identify forward-looking statements.
Such forward-looking statements are based on the beliefs of
management as well as assumptions made by and information currently
available to management. Actual results could differ materially
from those contemplated by the forward-looking statements as a
result of certain factors, including, but not limited to, delays in
planned clinical trials; the ability to establish that potential
products are efficacious or safe in preclinical or clinical trials;
the ability to establish or maintain collaborations on the
development of therapeutic candidates; the ability to obtain
appropriate or necessary governmental approvals to market potential
products; the ability to obtain future funding for developmental
products and working capital and to obtain such funding on
commercially reasonable terms; the Company's ability to manufacture
product candidates on a commercial scale or in collaborations with
third parties; changes in the size and nature of competitors; the
ability to retain key executives and scientists; and the ability to
secure and enforce legal rights related to the Company's products,
including patent protection. A discussion of these and other
factors, including risks and uncertainties with respect to the
Company, is set forth in the Company's filings with the SEC,
including its annual report on Form 10-K filed with the Securities
and Exchange Commission on February 19,
2019, as amended on July 24,
2019, as may be supplemented or amended by the Company's
Quarterly Reports on Form 10-Q. The Company disclaims any intention
or obligation to revise any forward-looking statements, whether as
a result of new information, future events or otherwise, except as
required by
law.
Investor
Contact
|
|
Ted Raad,
CEO
|
William Duke,
CFO
|
(781)
357-2333
|
(781)
357-2333
|
rclarke@pulmatrix.com
|
wduke@pulmatrix.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pulmatrix-receives-us-patent-covering-isperse-formulations-for-pulmazole-program-300903332.html
SOURCE Pulmatrix, Inc.